HR 2380, the Cellphone Jamming Reform Act of 2023, allows state and federal correctional facilities (like prisons and jails) to operate cellphone jamming systems to block wireless signals from contraband devices or communications involving individuals held in the facility. The bill restricts the Federal Communications Commission (FCC) from blocking such jamming systems, but requires facilities to limit jamming only to housing areas, have state facilities cover all costs, and consult with local law enforcement before implementation. It defines "jamming systems" broadly to include all necessary equipment and installation details. This bill directly affects correctional facilities seeking to prevent cell phone use by inmates, particularly for security purposes related to contraband. The law does not create new restrictions on cellphone use but changes how facilities can deploy jamming technology.
HR 1839, the Combating Illicit Xylazine Act, makes the illicit use and distribution of xylazine a federal crime by adding it to the Controlled Substances Act. The bill broadly defines xylazine to cover numerous chemical variants and prohibits human use or non-licit distribution, while preserving legitimate veterinary and pharmaceutical uses. It requires tracking xylazine in drug supply chains and mandates two reports to Congress within 1 and 4 years on its prevalence, sources, and whether it should be rescheduled. The bill directly affects individuals distributing or using xylazine illicitly, including as an additive to drugs like fentanyl, and aims to address its public health risks. Congress declared illicit xylazine an "emerging drug threat" under existing law.
HR 1812 requires the Federal Communications Commission (FCC) to study whether the Universal Service Fund (USF), which funds broadband access in rural and low-income areas, should expand who pays into the fund to ensure fairness. Within 120 days of enactment, the FCC must complete this study and report findings to Congress. By one year after enactment, the FCC must also develop new rules to reform the USF contribution system, specifically expanding who contributes. This directly affects telecommunications companies that pay into the USF, as the changes could shift funding responsibilities, potentially impacting broadband costs for consumers and businesses. The bill aims to make the funding system more equitable without specifying final changes.
The Women's Health Protection Act of 2023 would protect access to abortion services by prohibiting states from imposing restrictions that are more burdensome than those for comparable medical procedures. The bill would ensure people can obtain abortion services before fetal viability without unnecessary limitations like mandatory waiting periods or biased counseling, and after viability when necessary to protect the patient's life or health. It would preempt state laws that conflict with these protections and allow for civil enforcement actions to challenge restrictive state laws. This bill directly affects people seeking abortion services (including transgender and nonbinary individuals who can become pregnant), health care providers, and states that have implemented abortion restrictions.
The Safe Students Act (HR 2502) repeals the Gun-Free School Zones Act of 1990, which had prohibited possessing firearms in federally designated school zones under federal law. It also amends related sections of Title 18 (U.S. Code) to remove references to the repealed law and adjust section numbering. This bill does not establish a new federal rule for school zones; it solely eliminates the existing federal prohibition on firearms in school zones. The repeal means the federal government would no longer enforce this specific ban, though state laws may continue to regulate firearms in schools.
HR 2539 permanently extends the New Markets Tax Credit (NMTC) program, which incentivizes private investment in low-income communities. The bill directly affects community development financial institutions (CDFIs) and investors who fund projects in designated low-income areas by ensuring the credit remains available beyond 2025. Key provisions include automatically adjusting the credit amount annually for inflation starting in 2024 and clarifying that the credit can be used to offset alternative minimum tax liability. This maintains the program’s effectiveness in channeling capital to underserved neighborhoods without changing eligibility or funding levels.
This bill amends the law governing Basic Allowance for Housing (BAH) for uniformed service members stationed in the U.S. It changes the calculation method so that BAH amounts must equal the actual monthly cost of adequate housing in each location, as determined by the Secretary of Defense. This directly affects active-duty service members and their families who receive BAH for housing. The key provision replaces the previous formula with a requirement that BAH payments match local housing costs for members in the same pay grade and dependency status. The change ensures BAH reflects current housing expenses rather than an older calculation method.
This joint resolution nullifies the final rule issued by the Consumer Financial Protection Bureau titled Small Business Lending under the Equal Credit Opportunity Act (Regulation B) and published on May 31, 2023. The rule requires financial institutions to collect and report to the bureau credit application data for small businesses. On July 31, 2023, the U.S. District Court for the Southern District of Texas ordered the bureau not to implement or enforce the rule until a related pending case is resolved.
Simplifying Management, Access, Reallocation, and Transfer of Spectrum Act or the SMART Spectrum Act This bill requires the National Telecommunications and Information Administration to implement an incumbent informing capability in its regulation of the electromagnetic spectrum. The bill also outlines minimum requirements for the capability that address protection of classified information and other matters. Incumbent informing capability is a mechanism that facilitates the sharing of spectrum allocated for both federal and nonfederal uses; it enables federal users to reliably inform nonfederal users when and where the federal systems are operating in order to manage harmful interference between the federal and nonfederal uses.
HCONRES 32 is a symbolic resolution supporting International Transgender Day of Visibility, introduced in the U.S. House of Representatives on March 30, 2023. It encourages Americans to observe the day through ceremonies and activities, celebrates transgender achievements, and recognizes the community's fight for dignity amid ongoing discrimination and anti-trans legislation. The resolution does not create new laws or policies - it is a non-binding statement of support, referencing over 700 anti-trans bills introduced in 2021-2023 that target education, healthcare, and identity documents. It directly acknowledges transgender individuals and their contributions without altering any legal rights or obligations.
This bill creates a legal process allowing generic drug manufacturers to challenge inaccurate patent listings by brand-name drug companies. Specifically, it permits generic applicants to file lawsuits seeking court orders to correct or delete misleading "use codes" in patent records related to a drug's method of use. This directly affects generic drug makers and brand-name sponsors who list patents for drug applications under FDA approval pathways. The key mechanism requires courts to address listings that don't match actual patents, cover unrelated uses, or are overly broad, aiming to clear patent-related barriers for generic competition.
The ADAPT 2.0 Act (S 1132) allows U.S. drug manufacturers to seek approval for new drugs using clinical and safety data from countries where the drug is already approved, such as the United Kingdom and South Africa. It requires the FDA to review these applications within 90 days and automatically approve them if the drug meets specific criteria, including being approved in the foreign country, safe, effective, and meeting manufacturing and patent requirements. The bill mandates the FDA to establish a new Foreign Drug Review Advisory Committee to evaluate applications within 60 days and publish approval decisions online. It also requires sponsors to conduct post-approval studies for certain drugs and submit promotional materials for review before dissemination. This law directly affects drug manufacturers seeking faster U.S. market access and the FDA’s review process for foreign-approved therapies.
